10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
The Parkinson’s disease (PD) market is expected to almost triple in sales in the seven major markets (7MM: The USA, France, Germany, Spain, Italy, the UK, and Japan) by 2029, rising from $4 billion in 2021 to $11.5 billion in 2029 at an impressive 12.6% compound annual growth rate (CAGR). 11 August 2021
Raman Sehgal, the founder of ramarketing, provides an Expert View on how pharmaceutical and life sciences businesses can market themselves in the post-pandemic environment. 10 August 2021
US biotech Seagen and Chinese biopharma RemeGen have announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted antibody-drug conjugate (ADC). 10 August 2021
German biotech BioNTech saw its shares close up 15% at $447.23 on Monday, after it provided an update on its corporate progress and reported financial results for the second quarter ended June 30, 2021. 10 August 2021
Shares of Canada’s Liminal BioSciences shot up nearly 28% to $3.65 by close of trading on Monday, after it announced that, its subsidiary Prometic Biotherapeutics (PBT) has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $105 million. 10 August 2021
US biotech bluebird bio yesterday reported financial results and business highlights for the second quarter ended June 30, 2021, which failed to impress investors, so the stock tumbled 27.5% to $18.16 by close of trading. 10 August 2021
The Russian government is considering a further tightening of public procurements of drugs for state needs by introducing the “second extra” principle, when the application of a Russian company that failed to localize the production of raw materials within the country will be rejected, according to recent statements made by some senior state officials and some local media reports. 10 August 2021
Russian pharmaceutical manufacturers have begun to compete for the production of generics based on bevacizumab, marketed by Swiss pharma giant Roche as Avastin, one of the most expensive and demanded cancer treatments, for which the value of state purchases currently exceeds 10 billion roubles ($136 million) a year, reports The Pharma Letter’s local correspondent. 10 August 2021
Australia’s Therapeutic Goods Administration (TGA) has granted provisional registration to the COVID-19 Vaccine Moderna in Australia for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus in individuals 18 years of age and older, with the news sending the vaccine’s producer. 10 August 2021
A self-styled pioneer that promises to develop and deliver innovative medicines to patients at radically lower prices, is to raise up to $1.8 billion via a combination with special purpose acquisition company (SPAC) CM Life Sciences III, as it looks to accelerate its growth. 9 August 2021
US biotech BioMarin Pharmaceutical recently presented positive one-year results from its GENEr8-1 Phase III trial, in which adults with severe hemophilia A are treated with the gene therapy Roctavian (valoctocogene roxaparvovec). 9 August 2021
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) significantly improved progression-free survival in the Phase III DESTINY-Breast03 head-to-head trial versus trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. 9 August 2021
USA-based cancer specialist Epizyme today announced a collaboration with Chinese biotech Hutchmed to research, develop, manufacture and commercialize Tazverik (tazemetostat) in Greater China, including mainland China, Hong Kong, Macau and Taiwan (the Territory). 9 August 2021
The Indian subsidiary of Anglo-Swedish pharma major AstraZeneca has reported a 45.03% decline in its net profit to $1.37 million for the June ended fiscal quarter. 9 August 2021
Roche has announced a successful trial outcome with Polivy (polatuzumab vedotin), an anti-CD79b antibody-drug conjugate (ADC) currently under investigation for the treatment of several types of non-Hodgkin's lymphoma (NHL) that the company is developing using Seagen ADC technology. 9 August 2021
Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). 9 August 2021
Shares of Spectrum Pharmaceuticals fell nearly 30% on Friday, after the US oncology specialist revealed yet another delay in the approval process for its lead product candidate Rolontis (eflapegrastim). 9 August 2021
Following the announcement on Friday that the board of Vectura had accepted an improved takeover offer from private equity group Carlyle of 155 pence a share, Philip Morris has increased its previous offer for the UK inhaled medicines company. 9 August 2021
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in the USA, the first generic to its reference medicine to be approved by the US Food and Drug Administration (FDA). 11 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of the Quarterly Biosimilar Market Report in the United States. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024